Polysaccharide of Escherichia coli in the Prevention of Recurrent Urinary Tract Infection: An Evidence-Based Review
Introduction: Recurrent urinary tract infection is frequent and it is related to morbidity, costs and growing antibiotic resistance. OM 8930 vaccine is composed by Escherichia coli polysaccharide and it is a possible prophylactic measure, but there is doubt as to its effectiveness.Material and Metho...
| Autor principal: | |
|---|---|
| Outros Autores: | , , , |
| Formato: | article |
| Idioma: | por |
| Publicado em: |
2018
|
| Assuntos: | |
| Texto completo: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9367 |
| País: | Portugal |
| Oai: | oai:ojs.www.actamedicaportuguesa.com:article/9367 |
| Resumo: | Introduction: Recurrent urinary tract infection is frequent and it is related to morbidity, costs and growing antibiotic resistance. OM 8930 vaccine is composed by Escherichia coli polysaccharide and it is a possible prophylactic measure, but there is doubt as to its effectiveness.Material and Methods: We performed a systematic review in evidence-based medicine databases with rigorous bibliography selection.Results: We found an effective decrease of recurrences in test groups.Discussion: We recommend the administration of the vaccine as prophylaxis of recurrent cystitis.Conclusion: The vaccine has impact on the recurrent cystitis relapse rate. We suggest that more studies be carried out to evaluate the vaccine cost-benefit and its effectiveness in complicated urinary infections. |
|---|